M&T Bank Corp Cuts Position in Edwards Lifesciences Corporation $EW

Key Points

• M&T Bank Corp cut its stake in Edwards Lifesciences by 78.8% in Q4, selling 23,295 shares and leaving the fund with 6,277 shares worth about $535,000.
• Edwards beat Q1 estimates with $0.78 EPS versus $0.73 expected and $1.65B revenue versus $1.60B expected, and set FY2026 guidance of $2.95–3.05 EPS (consensus price target $95.65, average rating "Moderate Buy").
• Insiders sold 86,058 shares (~$7.12M) over the quarter, including VP Donald E. Bobo Jr.'s sale of 24,000 shares (~$2.01M), while institutional investors continue to own about 79.46% of the stock.

M&T Bank Corp lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 78.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,277 shares of the medical research company's stock after selling 23,295 shares during the period. M&T Bank Corp's holdings in Edwards Lifesciences were worth $535,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Level Four Advisory Services LLC boosted its stake in shares of Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after buying an additional 119 shares during the last quarter. Colonial Trust Co SC raised its holdings in shares of Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock worth $2,504,000 after purchasing an additional 120 shares during the period. Evermay Wealth Management LLC raised its holdings in shares of Edwards Lifesciences by 4.0% in the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock worth $282,000 after purchasing an additional 128 shares during the period. Howard Capital Management Inc. raised its holdings in shares of Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock worth $322,000 after purchasing an additional 132 shares during the period. Finally, Florida Trust Wealth Management Co raised its holdings in shares of Edwards Lifesciences by 1.5% in the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company's stock worth $751,000 after purchasing an additional 132 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on EW. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a "hold" rating in a report on Friday, April 24th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a report on Friday, April 24th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a "buy" rating in a report on Tuesday, January 20th. BTIG Research lifted their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, April 24th. Finally, TD Cowen raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $95.65.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares of the company's stock, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. The trade was a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 86,058 shares of company stock valued at $7,118,636. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.7%

Shares of EW stock opened at $84.08 on Friday. The stock has a market capitalization of $48.47 billion, a price-to-earnings ratio of 44.72, a PEG ratio of 2.11 and a beta of 0.87. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The company's fifty day simple moving average is $82.08 and its two-hundred day simple moving average is $82.47. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. The business's quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.